OKYO Pharma's OK-101 Hits Key Endpoints in Phase 2 Dry Eye Trial
Ticker: OKYO · Form: 6-K · Filed: Jan 8, 2024 · CIK: 1849296
| Field | Detail |
|---|---|
| Company | Okyo Pharma LTD (OKYO) |
| Form Type | 6-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: clinical-trial, drug-development, biotechnology, positive-results
TL;DR
**OKYO Pharma's dry eye drug OK-101 just crushed its Phase 2 trial, big win!**
AI Summary
OKYO Pharma Ltd. announced on January 8, 2024, that its drug candidate, OK-101, successfully met both sign and symptom endpoints with statistical significance in its first-in-human Phase 2 trial for patients with dry eye disease. This positive trial outcome for OK-101, a potential treatment for a common condition, is crucial for investors as it de-risks the drug's development and could lead to significant future revenue if it progresses to market, potentially boosting the stock price.
Why It Matters
This positive Phase 2 trial result for OK-101 significantly de-risks the drug's development path, potentially leading to a new treatment for dry eye disease and increased value for OKYO Pharma shareholders.
Risk Assessment
Risk Level: medium — While Phase 2 success is positive, the drug still needs to pass Phase 3 trials and gain regulatory approval, which are significant hurdles.
Analyst Insight
A smart investor would closely monitor OKYO Pharma's next steps regarding OK-101's development, particularly any announcements about Phase 3 trials or partnerships, as this positive Phase 2 data could signal significant future growth potential.
Key Players & Entities
- OKYO Pharma LTD (company) — the registrant announcing the trial results
- OK-101 (drug) — the drug candidate for dry eye disease
- Keeren Shah (person) — Chief Financial Officer of OKYO Pharma LTD
- January 8, 2024 (date) — date of the announcement and filing
Forward-Looking Statements
- OKYO Pharma will proceed with a Phase 3 clinical trial for OK-101. (OKYO Pharma LTD) — high confidence, target: within 12-18 months
- The stock price of OKYO Pharma LTD will see a positive reaction due to the successful Phase 2 results. (OKYO Pharma LTD) — high confidence, target: short-term
FAQ
What is the primary purpose of this 6-K filing by OKYO Pharma LTD?
The primary purpose of this 6-K filing is to announce that OKYO Pharma LTD's drug candidate, OK-101, successfully achieved statistical significance for both sign and symptom endpoints in its first-in-human Phase 2 trial for patients with dry eye disease, as stated on January 8, 2024.
Which specific drug candidate is mentioned in the filing, and what condition is it intended to treat?
The specific drug candidate mentioned is OK-101, and it is intended to treat patients with dry eye disease, as detailed in the announcement furnished as Exhibit 99.1 on January 8, 2024.
What was the key outcome of the Phase 2 trial for OK-101?
The key outcome of the Phase 2 trial for OK-101 was that it successfully achieved statistical significance for both sign and symptom endpoints in patients with dry eye disease, according to the January 8, 2024 announcement.
Who signed the 6-K report on behalf of OKYO Pharma LTD and what is their title?
The 6-K report was signed by Keeren Shah, who holds the title of Chief Financial Officer for OKYO Pharma LTD, with the signing date of January 8, 2024.
What is the significance of Exhibit 99.1 mentioned in the filing?
Exhibit 99.1 is a News Announcement, dated January 8, 2024, which contains the detailed information about OKYO Pharma's announcement regarding the successful Phase 2 trial results for OK-101.
Filing Stats: 344 words · 1 min read · ~1 pages · Grade level 15 · Accepted 2024-01-08 07:00:33
Filing Documents
- form6-k.htm (6-K) — 20KB
- ex99-1.htm (EX-99.1) — 29KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001493152-24-001658.txt ( ) — 60KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: January 8, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated January 8, 2024 4